ResultsIQ

ResultsIQ › Latest results › Blue Jet Healthcare Limited

Blue Jet Healthcare Limited Q1 FY26 results deck summary

NSE: BLUEJET · BSE: 544009

Results deck of 22 Jul 2025, summarised by AI from the filing.

Q1 FY26 revenue from operations ₹3,548 mn, up 4.2% QoQ and 117.8% YoY, with PAT ₹912 mn and EBITDA margin 34.1%.

Key takeaways

  1. Revenue Revenue from operations ₹3,548 mn in Q1 FY26, up 4.2% QoQ from ₹3,404 mn and up 117.8% YoY from ₹1,629 mn, driven by higher PI & API sales.
  2. PAT PAT ₹912 mn in Q1 FY26, down 17.2% QoQ from ₹1,101 mn and up 141.3% YoY from ₹378 mn.
  3. Gross margin Gross margin fell to 48.4% in Q1 FY26 from 54.7% in Q4 FY25 on product mix shift and reduced inventory levels.
  4. PI & API Pharma intermediates and API revenue ₹602 mn in Q1 FY26 vs ₹349 mn in Q1 FY25, YoY growth 356.4%.
  5. Customer concentration Top 4 contrast media players hold ~75% of global market share.

Original filing on BSE

Blue Jet Healthcare Limited Q1 FY27 results

As filed: Revenue ₹293 cr (−17% year on year), EBITDA ₹98.1 cr (−20% year on year), PAT ₹78.3 cr (−14% year on year), EBITDA margin 33.5% (−90 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹235 cr (−31% year on year), EBITDA ₹71.3 cr (−49% year on year), PAT ₹64.3 cr (−42% year on year), EBITDA margin 30.4% (−1,000 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Other income 26% of PBT. Share price after the results: +17.2% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹192 cr (−39% year on year), EBITDA ₹46.9 cr (−62% year on year), PAT ₹40.2 cr (−59% year on year), EBITDA margin 24.4% (−1,000 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Profit fell 23% from last quarter. Share price after the results: −18.8% in 28 days (Nifty 500: −9.6%).
  • Q2 FY26: Revenue ₹165 cr (−21% year on year), EBITDA ₹56.0 cr (−20% year on year), PAT ₹52.0 cr (−10% year on year), EBITDA margin 33.9% (+29 bps). Score 6 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin rose 29 bps year on year. Other income 35% of PBT. Revenue fell 54% from last quarter. Share price after the results: −17.7% in 30 days (Nifty 500: −0.3%).
  • Q1 FY26: Revenue ₹355 cr (+118% year on year), EBITDA ₹122 cr (+184% year on year), PAT ₹91.0 cr (+139% year on year), EBITDA margin 34.4% (+799 bps). Score 85 of 100, Above trend. EBITDA margin rose 799 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 17% from last quarter. Share price after the results: −23.5% in 30 days (Nifty 500: −1.0%).
  • Q4 FY25: Revenue ₹340 cr (+85% year on year), EBITDA ₹140 cr (+164% year on year), PAT ₹110 cr (+182% year on year), EBITDA margin 41.2% (+1,000 bps). Score 100 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +24.0% in 30 days (Nifty 500: +2.5%).
  • Q3 FY25: Revenue ₹318 cr (+90% year on year), EBITDA ₹124 cr (+125% year on year), PAT ₹99.0 cr (+209% year on year), EBITDA margin 39.0% (+606 bps). Score 100 of 100, Above trend. EBITDA margin rose 606 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹208 cr (+15% year on year), EBITDA ₹70.0 cr (+13% year on year), PAT ₹58.0 cr (+21% year on year), EBITDA margin 33.7% (−60 bps). Score 55 of 100, In line with trend. EBITDA margin fell 60 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Blue Jet Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.